Jiangsu Hengrui Medicine

Jiangsu Hengrui Medicine Co., Ltd., a pharmaceutical company, researches, develops, manufactures, and commercializes medicine worldwide. The company is developing Apatinib, Pyrotinib, Mecapegfilgrastim, SHR3680, SHR3162, SHR9549, SHR2554, SHR1459, SHR-1309, SHR-A1201, Camrelizumab, Famitinib, SHR-1316, SHR-1501, SHR-1603, SHR-1701, SHR-1702, and SHR-A1403 for oncology, metabolic, pain, autoimmune, and other indications. The company was founded in 1970 and is based in Lianyungang, China.

Founded in 1970, Jiangsu Hengrui Pharmaceuticals was originally state-owned and called Lianyungang Pharmaceutical Factory. Headquartered in Lianyungang, Jiangsu, it was established in its current form in 1977. 

Jiangsu Hengrui Medicine develops, manufactures, and markets a variety of medicines and medical packing materials. The Company's products include anti-tumour medicines, painkillers, anti-infection medicines, aluminium foil, and other related products. Taking the slogan “Science & Technology for a Better Life”, Hengrui Medicine is dedicated to researching, developing, and promoting innovative medicine with high quality. They help doctors to solve clinical problems, help patients be cured, and help improve the standard of health for all humanity.

The company was listed on the Shanghai Stock Exchange in 2000 and now has locations in China, the United States, Germany, Switzerland, Japan, and Australia.

“Promote a healthier life for humankind through advancements in science.”

“Become a global biopharmaceutical group through innovation.”